Source comparison
BPC-157 for Osteoarthritis: Treatment Comparison
This table compares BPC-157 to conventional osteoarthritis interventions across mechanism, evidence level, and practical considerations. BPC-157 Upregulates VEGF, activates FAK-paxillin pathway, increases collagen type II synthesis Preclinical (animal models)
This comparison does not assign a generated winner or score.
- This table compares BPC-157 to conventional osteoarthritis interventions across mechanism, evidence level, and practical considerations.
- BPC-157
- Upregulates VEGF, activates FAK-paxillin pathway, increases collagen type II synthesis
- Preclinical (animal models) + observational human case series
- 250–500 mcg daily subcutaneous, 12–16 weeks
- Animal studies show 25–35% cartilage thickness improvement; human imaging data limited
- Promising mechanism with strong preclinical data, but lacks Phase III human trials. Use remains investigational
- NSAIDs (ibuprofen, naproxen)
- Inhibits COX enzymes, reduces prostaglandin-mediated inflammation
- Extensive human RCTs
- 400–800 mg ibuprofen 2–3×/day as needed
- No structural benefit; may accelerate cartilage loss with chronic use
- Effective for symptom control but does not address underlying cartilage degeneration. Not disease-modifying
- Corticosteroid Injections
- Broad anti-inflammatory via glucocorticoid receptor activation
- Well-established in clinical practice
- 40–80 mg triamcinolone intra-articular, 3–4 month intervals
- Suppresses chondrocyte activity; repeated use associated with cartilage thinning
- Provides 6–12 week symptom relief but inhibits cartilage repair mechanisms. Limited to 3–4 injections/year
- Hyaluronic Acid Injections
- Viscosupplementation. Temporarily restores synovial fluid viscosity
- Mixed evidence; meta-analyses show modest benefit
- 3–5 weekly injections (20–30 mg/injection)
- No regenerative effect; symptom relief only
- Temporary lubrication benefit for 3–6 months. Does not modify disease progression
- Platelet-Rich Plasma (PRP)
- Delivers growth factors (PDGF, TGF-β, IGF-1) to stimulate tissue repair
- Moderate-quality human trials show symptom improvement
- 3–6 mL intra-articular, 1–3 injections spaced 2–4 weeks
- Some studies show modest cartilage quality improvement on MRI at 12 months
- More evidence than BPC-157 for symptom improvement; structural benefit still debated. Response highly variable